Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens J Holst

Showing results (1-10 of 786) with videos related to

Pageof 79
Sort By:
Journal of Internal Medicine|January 4, 2022
Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?Jens J Holst
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?Jens J Holst
Diabetologia|October 12, 2020
Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic isletsBerit Svendsen, Jens J Holst
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 20, 2021
What is Diabetes Remission?Jens J Holst, Sten Madsbad
Cardiovascular Research|August 4, 2022
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonistsSten Madsbad, Jens J Holst
Current Opinion in Endocrinology, Diabetes, and Obesity|November 3, 2009
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advancesMeena Asmar, Jens J Holst
Lancet (London, England)|March 11, 2019
Bariatric surgery-which procedure is the optimal choice?Sten Madsbad, Jens J Holst
The Lancet. Diabetes & Endocrinology|April 8, 2017
Glycaemic control and weight loss with semaglutide in type 2 diabetesSten Madsbad, Jens J Holst
Diabetes|September 25, 2014
GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgerySten Madsbad, Jens J Holst
Nature Reviews. Endocrinology|July 9, 2016
Guidelines: Surgical or medical therapy for patients with obesity and T2DM?Sten Madsbad, Jens J Holst
Pageof 79

Showing results (1-10 of 786) with videos related to

Sort By:
Pageof 79
Journal of Internal Medicine|January 4, 2022
Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?Jens J Holst
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?Jens J Holst
Diabetologia|October 12, 2020
Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic isletsBerit Svendsen, Jens J Holst
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 20, 2021
What is Diabetes Remission?Jens J Holst, Sten Madsbad
Cardiovascular Research|August 4, 2022
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonistsSten Madsbad, Jens J Holst
Current Opinion in Endocrinology, Diabetes, and Obesity|November 3, 2009
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advancesMeena Asmar, Jens J Holst
Lancet (London, England)|March 11, 2019
Bariatric surgery-which procedure is the optimal choice?Sten Madsbad, Jens J Holst
The Lancet. Diabetes & Endocrinology|April 8, 2017
Glycaemic control and weight loss with semaglutide in type 2 diabetesSten Madsbad, Jens J Holst
Diabetes|September 25, 2014
GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgerySten Madsbad, Jens J Holst
Nature Reviews. Endocrinology|July 9, 2016
Guidelines: Surgical or medical therapy for patients with obesity and T2DM?Sten Madsbad, Jens J Holst
Pageof 79